Allogeneic (allo) hematopoietic cell transplantation (HCT) is the only curative treatment
option for patients suffering from chemotherapy-refractory or relapsed hematological …

Haploidentical stem cell transplantation (haploSCT) has advanced to a common procedure
for treating patients with hematological malignancies and immunodeficiency diseases …

Background Effective treatments are still needed to reduce the severity of symptoms, time of
hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes …

Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak
significantly delaying the hope for the virus' complete eradication. In the absence of effective …

T-cell depletion of an HLA-haploidentical (haplo) graft is often used to reduce the risk of graft-
versus-host disease (GVHD), but the lack of donor T cells in the infused product may lead to …

Depletion of αβ T cells from the graft prevents graft-vs.-host disease (GVHD) and improves
outcome of HSCT from haploidentical donors. In a randomized trial, we aimed to evaluate …

Abstract The CD45RA T cell depletion (TCD) method has been used to deplete naive T
cells, preventing graft-versus-host disease (GVHD) but preserving memory cells, providing …

The outcome of allogeneic hematopoietic cell transplantation (allo-HCT) largely depends on
the development and management of graft-versus-host disease (GvHD), infections, and the …

Abstract Human herpesvirus-6 (HHV-6) infection is increasingly recognized among
allogeneic hematopoietic stem cell transplantation (HSCT) recipients, with 30% at risk of …

The barriers to HLA-mismatched or haploidentical hematopoietic stem cell transplantation
(HSCT), namely GvHD and graft failure, have been overcome with novel transplant …